New Delhi: Dr. Reddy’s Laboratories on Tuesday said it will launch Molflu (Molnupiravir) at Rs 35 per capsule to treat COVID-19 in the country.
Molflu will be priced at Rs 35 per capsule, a spokesperson of the Hyderabad-based drug maker said in a statement.
With 10 capsules per strip, the total course of 40 capsules over 5 days would cost Rs 1,400, making it among the most affordable treatment options available to patients, it added.
“Molflu is expected to be available from early next week in pharmacies throughout the country with particular focus on states with high caseload of COVID-19,” the spokesperson noted.
Last year, Dr Reddy’s entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).
In a first-of-its-kind collaboration in the Indian pharmaceutical industry, a Dr Reddy’s-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the Phase III clinical trial of Molnupiravir in India, and presented its findings to the Subject Expert Committee.
Last week, Dr Reddy’s received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market oral antiviral drug Molnupiravir capsules 200 mg for the treatment of adult patients with COVID-19 who have high risk of progression of the disease including hospitalisation or death.
Molflu will be manufactured at a USFDA-approved facility, and the drug maker has made adequate capacity preparations to ensure that it is able to help patients in need, it said.
- China asks Taliban to meet expectations of int’l community for recognition
- Pakistan to compensate 36 Chinese victims of hydro project terror attack
- What the Tonga volcanic eruption tells about global telecom system
- WHO counts 18 million virus cases last week as omicron slows
- Pfizer chief Albert Bourla wins $1 million Genesis Prize
- US, allies pledge unity on Russia; to do what isn’t as clear